Luminescence imaging technology developer Lightpoint Medical received a 2.4 million euro grant from the European Commission that will enable the company to carry out a large-scale clinical trial in breast cancer.
The study aims to cut the rate of reoperations in breast cancer, potentially preventing many thousands of women from facing additional surgery, and providing significant cost savings to national healthcare systems, the firm said.
The grant is part of the Horizon 2020 European Union Framework Program for Research and Innovation. Using the funding, Lightpoint Medical will evaluate the LightPath imaging system as a means of identifying cancer in a study involving more than 300 breast cancer patients at several hospitals in the U.K., Germany, and France.
